Showing 621-630 of 671 results for "".
- Lithera Changes Name to Neothetics, Inc.https://practicaldermatology.com/news/20140812-lithera_changes_name_to_neothetics_inc/2459146/In a move the company says is intended to stregthen its positioning as a clinical stage, specialty pharmaceutical company developing novel therapeutics for the aesthetics market, Lithera has changed its name to Neothetics, Inc. President and CEO of Neothetics George Mahaffey said, "Our ne
- Cynosure Appoints Timothy W. Baker as Presidenthttps://practicaldermatology.com/news/20140730-cynosure_appoints_timothy_w_baker_as_president/2459154/The Board of Directors of Cynosure, Inc., which develops and markets laser- and light-based aesthetic treatments for non-invasive and minimally invasive applications, promoted Executive Vice President, Chief Operating Officer and Chief Financial Officer Timothy W. Baker to Presi
- Valeant Pharmaceuticals Completes Acquisition of PreCision Dermatologyhttps://practicaldermatology.com/news/20140708-valeant_pharmaceuticals_completes_acquisition_of_precision_dermatology/2459178/Valeant Pharmaceuticals International, Inc. has completed the previously announced acquisition of PreCision Dermatology, Inc. PreCision develops and markets high quality dermatology products with leading products such as Locoid, Hylatopic, and Clindagel.
- FDA Approves Sivextro to Treat Skin Infections in Adultshttps://practicaldermatology.com/news/20140624-fda_approves_sivextro_to_treat_skin_infections_in_adults/2459192/The FDA approved Sivextro (tedizolid phosphate), a new antibacterial drug, to treat adults with skin infections. Sivextro, which is marketed by Cubist Pharmaceuticals, is approved to treat patients with acute bacterial skin and skin structure infections (ABSSSI) caused by certain susceptible bact
- Valeant Pharmaceuticals Receives FDA Clearance For Restylane Silkhttps://practicaldermatology.com/news/20140616-valeant_pharmaceuticals_receives_fda_clearance_for_restylane_silk/2459205/The FDA issued marketing clearance for Valeant Pharmaceuticals International, Inc.'s Restylane Silk Injectable Gel with 0.3% Lidocaine for submucosal implantation for lip augmentation and dermal implantation for correction of perio
- Envy Medical Receives Growth Capital Investment from HCP & Companyhttps://practicaldermatology.com/news/20140604-envy_medical_receives_growth_capital_investment_from_hcp__company/2459218/Chicago-based HCP & Company is providing a growth capital investment to Envy Medical to support sales and marketing initiatives, while also allowing the company to accelerate the development and introduction of new skincare offerings designed to meet the growing demand for healthier skin tone, te
- Revance Therapeutics Added to Russell 2000(R) and 3000(R) Indexeshttps://practicaldermatology.com/news/20140401-revance_therapeutics_added_to_russell_2000r_and_3000r_indexes/2459286/Revance Therapeutics, Inc. (Nasdaq:RVNC), today announced the company was added to the Russell 2000® and Russell 3000® Indexes following the reconstitution of Russell Investment Group's family of U.S. indexes after market close on March 31, 2014.
- Frost & Sullivan Commends Sensus for the Development of SRT-100™ and SRT-100 Vision™, its Low-energy Radiation Therapy Systems for Treating Skin Cancerhttps://practicaldermatology.com/news/20140331-frost__sullivan_commends_sensus_for_the_development_of_srt-100_and_srt-100_vision_its_low-energy_radiation_therapy_systems_for_treating_skin_cancer/2459289/Based on its recent analysis of the non-melanoma skin cancer therapy market, Frost & Sullivan recognizes Sensus Healthcare LLC with the 2014 North American Frost & Sullivan Award for New Product Innovation Leadership. Sensus uses a technique known as superficial radiation therapy (SRT) in its two lo
- Mirvaso Approved by the European Commissionhttps://practicaldermatology.com/news/20140226-mirvaso_approved_by_the_european_commission/2459330/The European Commission has granted marketing authorization in Europe for Galderma's Mirvaso (brimonidine) 3 mg/g gel. Mirvaso, an alpha-2 adrenergic receptor agonist that acts rapidly and can last for up to 12 hours, is indicated for the symptomatic tr
- Alma Lasers Debuts its 2014 Webinar Serieshttps://practicaldermatology.com/news/20140116-alma_lasers_debuts_its_2014_webinar_series/2459372/In a complimentary webinar series, industry experts will showcase their success building local market awareness to drive practice results. Spearheaded by Alma Lasers , the informative ses